Translational Drug Development (TD2)’s Post

Multi-cancer detection tests are pushing the boundaries of how we consider a biomarker a success. This paper in JNCI revisits how to evaluate these tests. https://lnkd.in/gi8kATfx

📝Today we share the #Review "Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors" 👨🔬by Qiuqiang Chen et al. Huzhou University Find out more here👉 https://lnkd.in/dHMQUY3R Keywords: CAR (chimeric antigen receptor); antigen; heterogeneity

Jennifer Herrera-Mullar, MGC, LCGC, discusses the takeaway points of one of Ambry’s poster presentations at #CGC2024. This summary explores two important aspects of gene-disease validity curation: how scoring methods have evolved over time and how GDV impacts the clinical utility of multi-gene panel testing. Watch the video to find out what trends they discovered. #genetictesting #hereditarycancer #variantclassification

More immune subsets are nice, but what is the value of the extra markers and subsets beyond conventional flow cytometry? If we took a conventional 13-marker flow panel, you get around ~108 cell subsets and states, almost exclusively T cells. Using our 42-marker mass cytometry panel, you get 792. (With our 25-marker spectral flow panel, it’s around 245). So what exactly are you missing out on with conventional flow? Multiple additional biomarkers, found through our own work and collaborations, associated with response and safety. More biomarkers found means more shots on goal for your clinical team, and every shot counts.

Multiplex your CAR T cell-mediated cytotoxicity and cytokine release assays. If you are at #AACR2024 today, visit Sierra Barnes’ poster #4017 (Section 2, Board 26) to learn more. Abstract Title: CAR T cell-mediated cytotoxicity and cytokine release in response to varying levels of antigen expression on target cells #AACR24 #CancerResearch #CellTherapy #CARTcell #AxionBio Viswanath Lanka, David Greenberg, Steven Book, Rachel Osby, Julien Bradley

In our latest blog, we break down our April community roundtable discussion and delve into the promising role of Bruton's tyrosine kinase (BTK) inhibitors in treating both classic HCL and HCL variants. This blog highlights current and past discussions, including patient experience and professional research. Check out the blog (and past entries) at: https://lnkd.in/gtmCJYyr

Our experience of clinical iPSC lines showing differntiation into NK cells. More information including live imaging of human iNK cells engulfing K562 cells, availabe through below link!

Join us for our upcoming webinar in June! 🗓️ 🔬 June 14: "Demonstrating the Interference of Tissue Processing in the Evaluation of Tissue Biomarkers: The Case of PD-L1" with Dr. Catarina Eloy and her valuable contribution, with Prof. Claudio Doglioni as Moderator.. Gain valuable insights into how tissue processing can impact biomarker evaluation, with a focus on PD-L1 analysis. Register here: 👉 June 14: Webinar Registration https://lnkd.in/dSGjCdiP Don't miss this opportunity to enhance your knowledge and stay updated with the latest developments in tissue biomarker evaluation. #DiapathWebinar #TissueProcessing #Biomarkers #PDL1 #HER2 #BreastCancer #MedicalWebinar #PathologyEducation

📢 A groundbreaking study titled "SFTPB in serum extracellular vesicles as a biomarker of progressive pulmonary fibrosis" by Takatoshi Enomoto and colleagues reveals that #serum #extracellularvesicles (#EVs) could be game-changing #biomarkers for the early detection of #progressivepulmonaryfibrosis (#PPF) #MedicalResearch #SerumEVs Read more about this study here: https://lnkd.in/g9vMq9T7

Accelerate Your Antibody Discoveries Visualize the expression and locale of proteins within tissues with 65+ IHC-validated antibodies. Download Data Pack Now: https://hubs.la/Q02r5fbs0. #CancerResearch #AntibodyDiscovery #IHC #BeatCancer